First-Ever Approved CRISPR-Based Therapy. CASGEVY™ (exagamglogene autotemcel), a CRISPR/Cas9 gene-edited therapy arising out of our collaboration with Vertex …

At CRISPR Therapeutics, our aim is to find cures for people suffering from serious diseases through transformative gene-based medicines.

Exa-cel, a CRISPR/Cas9 gene-edited therapy arising out of our collaboration with Vertex Pharmaceuticals Incorporated, has now been approved in some countries for certain eligible …

As a gene-editing tool, CRISPR/Cas9 has revolutionized biomedical research and enabled medical breakthroughs. CRISPR/Cas9 edits genes by precisely cutting DNA and then …

CASGEVY™ (exagamglogene autotemcel), a CRISPR/Cas9 gene-edited therapy arising out of our collaboration with Vertex Pharmaceuticals Incorporated, is approved in some countries for …

With CRISPR/Cas9, we can potentially engineer the genomes of cellular therapies to make them more efficacious, safer and available to a broader group of patients. At CRISPR Therapeutics, …

Dec 9, 2024 · The Investor Relations website contains information about CRISPR Therapeutics's business for stockholders, potential investors, and financial analysts.

Feb 13, 2024 · CRISPR Therapeutics and Vertex entered into a strategic research collaboration in 2015 focused on the use of CRISPR/Cas9 to discover and develop potential new treatments …

Jan 16, 2024 · CRISPR Therapeutics Announces U.S. Food and Drug Administration (FDA) Approval of CASGEVY™ (exagamglogene autotemcel) for the Treatment of Transfusion …

Jan 8, 2024 · CRISPR Therapeutics and Vertex entered into a strategic research collaboration in 2015 focused on the use of CRISPR/Cas9 to discover and develop potential new treatments …